as 01-21-2025 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 161.9M | IPO Year: | 2021 |
Target Price: | $11.36 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.65 | EPS Growth: | N/A |
52 Week Low/High: | $0.63 - $2.50 | Next Earning Date: | 11-07-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Attar Eyal C. | VOR | CHIEF MEDICAL OFFICER | Dec 27 '24 | Sell | $1.25 | 10,334 | $12,917.50 | 81,439 |
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
MT Newswires
22 days ago
TipRanks
25 days ago
GuruFocus.com
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.